Supercharging Development of Gamma Delta T Therapies
to Bring Life Saving and Cost-Effective Solid Tumor Treatments
to Patients in Need
With race to market for the first allogeneic and solid tumor targeting cell immunotherapy well and truly on, the explosive excitement in Gamma Delta T Therapies continues to increase, as we begin to see the early clinical data
read out on safety and efficacy.
The annual Gamma Delta T Therapies Summit returned as a 3 day virtual event gathering the world’s leaders harnessing GDT cells to bring to market the first effective, allogeneic cell therapy for solid tumors.
Developed with experts from Adicet Bio, Lava Therapeutics, IN8 Bio and other leading organizations, 100+ of your peers joined to be part of this unique opportunity to engage in interactive discussions on modulating cell activity through genetic engineering, enhancing the functionality of GDT cells through an improved understanding of their behaviour and how to effectively activate the cells.
Navigating across 3 content packed days at this industry-defining forum, focused on advancing the field to achieve clinical success, with dedicated, interactive formats exploring how to enhance the durability and efficient selective expansion of Gamma Delta T cells for improved safety, efficacy and manufacturability to bring to market best-in-class therapies to patients in need.
Speaker Faculty Includes:
VP of Research
Senior Research Fellow, Developmental Biology & Cancer Section
Zayed Center for Research, Great Ormond St Hospital, University College London Great Ormond St Institute of Child Health
Chief Scientific Officer